Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||trastuzumab and hyaluronidase-oysk injection|
|Trade Name||Herceptin Hylecta|
Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) is an injectable formulation consists of Herceptin (trastuzumab) and hyaluronidase, which demonstrates anti-tumor activity against ERBB2 (HER2)-positive breast cancer (PMID: 28625777). Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) is FDA-approved for use in patients with Erbb2 (Her2)-overexpressing and/or Erbb2 (Her2) amplified breast cancer (FDA.gov).
|DrugClasses||HER2 (ERBB2) Antibody 47|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|trastuzumab and hyaluronidase-oysk injection||trastuzumab and hyaluronidase-oysk injection||2||0|